Matching-Adjusted Indirect Comparisons of eGFR Slopes in the PROTECT study with UK RaDaR IgA Nephropathy Population and the Control Arm of NefIgArd
European Renal Association (ERA) Congress 2024
May 23 - 26, 2024
Stockholm
Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety
FILSPARI (sparsentan): Impact on Male Fertility
FILSPARI (sparsentan): Use in Transplant Patients
FILSPARI (sparsentan): Use in Patients With Severely Decreased eGFR in IgA Nephropathy
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study
FILSPARI (sparsentan): Changes in Blood Pressure and Hypotensive Events in FSGS
FILSPARI (sparsentan): Effect on Estimated Glomerular Filtration Rate (eGFR) in FSGS
FILSPARI (sparsentan): Dosing and Administration in Clinical Trials of FSGS
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet
Physiologically-Based Pharmacokinetic Model of Sparsentan to Evaluate Drug-Drug Interaction Potential